• All
  • --
  • ---
  • -2022
  • 2022-2
  • 2022-2-2-2
  • 2022-deltia-tipoy
  • 2022-deltia-tipoy-2-2
  • 2022-deltia-tipoy-2-2-2-2
  • 2023-deltia-typou
  • 2023-deltia-typou-2-2
  • 2024
  • 257-2
  • 257-2-2-2
  • 266-2
  • Announcements
  • Announcements 2025
  • Consolidated Financial Results
  • deltia-tipoy
  • deltia-tipoy-2-2
  • deltia-tipoy-2-2-2-2
  • Distribution of Divident
  • Events
  • FAQ
  • General Meetings and Corporate Actions
  • Insiders Transactions Disclosures
  • Invitations
  • invitations-2
  • Presentations
  • Press Kits
  • Press Releases
  • Regulated Information
  • Results 2024
  • Share Capital Increase
  • Uncategorized

  Peania, October 24th 2018 - Lavipharm S.A., pursuant to Article 19 of the European Parliament Regulation No 596/2014 and its Board dated 16/04/2014, hereby informs the investment community that T & A Holdings (Luxembourg) sarl, a company related to Lavipharm SA's Executive Chairman, Mr. Athanasios...

  Peania, December 6th 2018 - Lavipharm S.A., pursuant to Article 19 of the European Parliament Regulation No 596/2014 and its Board dated 16/04/2014, hereby informs the investment community that, on December 3rd, 2018, T & A Holdings (Luxembourg) sarl, a company related to Lavipharm SA's...

  Παιανία, 28 Απριλίου 2017 – Κατά το 2016, παρά τη μείωση της δημόσιας φαρμακευτικής δαπάνης, την περαιτέρω συμπίεση του κλάδου της Υγείας και τη συνεχιζόμενη αβεβαιότητα, η Lavipharm παρουσιάζει ενίσχυση του Κύκλου Εργασιών της, που προέρχεται κυρίως από τη σημαντική αύξηση των Πωλήσεων της εκτός...

  Peania, September 29th, 2017 – In the First Half of 2017, Lavipharm reports increased Consolidated Turnover mainly attributed to international sales, despite economic pressures, sustained regulatory constraints and decrease of the pharmaceutical market in Greece. At the same time, the sharp drop in loans and...